Evidence map›Paper›PMID 41199911›Full record

ArticleCase reports in hematology2025

Immune-Related Adverse Events in a Patient With Burkitt's Lymphoma During PD-1 Immune Consolidation Therapy: A Case Report.

Qi Zhang, Fankai Meng, Yang Cao, Xiaojian Zhu, Yicheng Zhang, Yi Xiao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qi ZhangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0002-2440-4451
Fankai MengDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xiaojian ZhuDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0002-2782-0311
Yicheng ZhangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0003-4300-0900
Yi XiaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0001-7274-6774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with Burkitt's lymphoma developed upper gastrointestinal adverse events during immune consolidation therapy following chemotherapy combined with autologous stem cell transplantation. Subsequent administration of vedolizumab as adjunctive therapy resulted in improvement of the patient's symptoms. This case is expected to provide a reference for the expanded application of PD-1 inhibitors in non-Hodgkin's lymphoma.

Indexed as

Burkitt's lymphomacase reportimmune-related adverse eventsPD-1

Identifiers

PMID41199911
PMCPMC12588755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.